HOME › Research Insight › Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Space is Marked by Increasing Investment
Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Space is Marked by Increasing Investment
The acute lymphocytic/lymphoblastic leukemia therapeutics market majorly consists of regimen therapies, namely, Hyper-CVAD, Linker, and CALGB 8811. In addition, Clolar, Arranon, and Oncaspar are the only available mono-therapy treatments in the market.
ERYTECH Pharma, Spectrum Pharmaceuticals (previously Talon Therapeutics) and Pfizer to lead the acute lymphocytic/lymphoblastic leukemia therapeutics pipeline with continuous innovations and new product launches in the forecast period (2013 to 2020)
In this market, Linker regimen and Hyper-CVAD regimen are the leading therapies, accounting for a share of approximately 65% - 70% of the overall market in 2013. Marqibo is the only drug in pipeline, which is currently commercially available in the market for treatment of acute lymphocytic/lymphoblastic leukemia in adults. A notable development in this market is that the market expiration of Arranon and Clolar (currently available drugs) will result in slight market erosion for these drugs. However, the overall market growth will be backed by the launch of new drugs (Graspa, Marqibo, and Inotuzumab Ozogamicin) in the market, which are currently under different stages of Phase III clinical trials.
The overall acute lymphocytic/lymphoblastic leukemia therapeutics market space is marked by increasing investment by market players towards development of innovative products. These investments are focused towards addressing the existing unmet needs in the market. Acquisition has been identified as one of the most prominent market entry strategies from most market players to enter the acute lymphocytic/lymphoblastic leukemia therapeutics market. Other than this, partnerships, collaborations, and joint ventures with research organizations are also widely accepted growth strategies by companies, to develop new products in the market.
Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market – (Pipeline Forecast & Market Forecast in G8 Countries) (2011 – 2020).
North - Dominion Plaza,
17304 Preston Road,
Suite 800, Dallas, TX 75252